Pretty impressive: Data were reported from 53 frontline unfit AML patients with a median age of 75 years and intermediate or adverse cytogenetic risk who had declined intensive therapy. Forty-five percent of patients had evidence of underlying myelodysplasia. Key findings presented by Dr. Fathi include:
- Of 49 efficacy-evaluable patients treated with 33A combined with either azacitidine or decitabine, the overall response rate was 76 percent. Complete remission (CR) or complete remission with incomplete platelet or neutrophil recovery (CRi) was observed in 35 patients (71 percent). The remission rate (CR+CRi) was similar between the two 33A and HMA combination treatment groups (71 percent combined with azacitidine and 72 percent combined with decitabine).
- Responses were observed in higher-risk patients, with remissions achieved in 16 of 22 patients (73 percent) with underlying myelodysplasia and 15 of 18 patients (83 percent) with adverse cytogenetics.
- Patients who achieved minimal residual disease included eight of 19 (42 percent) CR patients and five of 15 (33 percent) CRi patients.
- The median overall survival for all patients in the phase 1 trial is interim and expected to evolve. The estimated median overall survival for the first 25 patients enrolled in the study was 12.75 months, with a median follow-up of 12.58 months.
- Median relapse-free survival was 7.7 months (range, 0.0+ and 11.3+) with 27 patients (51 percent) remaining alive and on study as of last follow-up. The 30- and 60-day mortality rates were two and eight percent, respectively.
- The most common treatment-related adverse events of any grade occurring in 20 percent or more of patients were fatigue (57 percent), thrombocytopenia (53 percent), nausea (49 percent), febrile neutropenia (45 percent), and constipation and anemia (42 percent each)....
It's clear now that last week's run-up and this week's crawl-up have nothing to do with the Bakers. The Form 4 they filed today was for a relative handful of shares that Felix received as a director. So, last week's action was due to another big buyer, who hasn't yet reached the 5 percent reporting threshold, or to the usual and mysterious "market forces."
Well, I also agree (not with the Trump part) and I'm on record as opining that the Bakers are where they want to be in SGEN and are just sitting back now and waiting for the right bid at the right price at the right time. Guess we'll see tonight - if no Form 4 from them by tonight - it probably wasn't them.
Just a WAG, but I'm thinking that the Bakers have their SGEN stake right about where they want it now and are in the posture of sitting back and waiting for the right offer at the right price at the right time.
Pretty routine stuff, imo, and the modest dilution already was authorized long ago. It certainly does represent additional confidence in the outcome of the trials. Also, the careful delineation of what would happen (will happen) upon being acquired...that certainly seems noteworthy. In fact, one could argue that this sort of thing is arranged - and announced - to bolster employee loyalty ahead of and during acquisition.
Ya know, I don't think you're dreaming, assuming the company remains independent that long. But given the Bakers' recent purchases, their track record and Big Pharma's desperate needs for pipelines and science, I'm guessing that SGEN will be absorbed by the Borg within a year or so.
Kool, if I'm reading it right, Abbvie paid a 100 percent premium for Stemcentrx - that is, it doubled that company's market value overnight. So...yeah, I'd agree. That deal sets something of a floor for the inevitable buyout of the much-farther-ahead SGEN, imo.
Here are some highlights of today’s SGEN conference call:
- Though some analysts are calling today’s revenue results a miss, CEO Clay Siegall said that full-year guidance for Adcetris sales in U.S. and Canada remains at $255-275 million. He attributed the alleged miss, if it can be called that, on cyclical inventory and first-quarter seasonal sales issues.
- Asked how big Adcetris might be, he said: “We think the opportunity is vast.”
- He announced that SGEN is establishing a European operations base in Switzerland.
- He and his staff repeatedly expressed considerable excitement about Vadastuximab Talirine (SGN-CD33A). “This is clearly an active drug….,” Siegall said. “Stay tuned for more information.” Asked about seeking FDA breakthrough designation for 33A, he deferred from answering directly, but said: “We’re really encouraged with our data. ”
- He expressed significant confidence in the phase 1 data from ASG-15ME and ASG-22ME to be released at the ASCO annual meeting in June – regarding bladder cancer and other solid tumors.
- Regarding the big jump in R&D expenses, the company called the jump consistent with guidance and said it largely reflected work that was started to get the 33A program into pivotal trials.
I’m was distracted about half-way through the call and I’m sure I missed important elements, especially regarding the pipeline. As always, I urge you to listen to the replay.
You said they would beat. Wall Street says they missed. It doesn't matter other than it shows that you're still an idiot - and back on ignore.
At this stage of the business, imo, earnings reports are mostly insignificant - especially since SGEN consistently hits its sales targets - and they never seem to have an enduring affect on the share price. It's the pipeline and the trials (and the takeover potential) that are most significant, imo.
Adam Feuerstein @adamfeuerstein 19m19 minutes ago
$AGN $PFE breakup should be good for biotech/drug M&A.
CNBC Now @CNBCnow 8m8 minutes ago
BREAKING: Pfizer and Allergan will mutually terminate their merger tomorrow morning - sources (via @davidfaber)
According to the rumor mill, Pfizer is leaning toward abandoning its deal with Allergen, and biotech watchers are predicting that such an action - if it happens - could free up a lot of cash and unleash a bidding war between them (and others) for biotechs.
Right. As others noted, exactly four shares traded at that price and only 45 shares traded at a similarly depressed price. As usual, someone was trying to mess with our heads.
Don't quite understand the question. All of the purchases appear in the Bakers' SEC filings, which is the important thing, and you can find links to them on SGEN's website. (Also, each purchase has been noted on this message board, many with followup discussions.) If you're referring to the Yahoo finance page dedicated to SGEN, only SEC filings made by SGEN itself will show up there. The Bakers are required to make their own SEC filings regarding their purchases of SGEN shares, so those transactions wouldn't show up on a list of SEC documents filed by SGEN.
It appears from the grayed out (ignored) original post that you are responding to the multi-aliased, thinking-challenged, only-shows-up-on-red-days troll known here under the following names: fstout57/rickarooski/quadhole/quadhole1/mauihope/smelky/etc. His elevator never reaches the top floor. Take it from board veterans: It's really better not to feed the troll.
Interesting perspectives. Following the logic thread here, the Bakers obviously are buying hand over fist, with the intention of profiting from their action. They have a history of arranging or supporting biotech sales to Big Pharmas. At this point, as others have noted, the only way they can unwind their huge (and growing) position is through a sale of SGEN. As insiders, they can't be buying if an offer is on the table at the moment. Hence: They intend, perhaps in association with management, to control the terms of what is now the inevitable sale of SGEN. This means it will come 1. At a fair (high) price and 2. Very possibly through a bidding war, especially if a Goldman Sachs co-conspirator makes a lowball public offer and 3. At a time of their choosing, but - given recent actions on their part - very likely sooner than some have believed.